AstraZeneca has admitted that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions in lawsuits brought ...

AstraZeneca AZN3.10%increase; green up pointing triangle has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand. The vaccine — called Vaxzevria and ...

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic.

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

Nov 1 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday it would invest $245 million in French biotechnology company Cellectis (ALCLS.PA), opens new tab in a deal aimed at speeding ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Under the deal, AstraZeneca will enter ...

By Rebecca Robbins AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was ...

AstraZeneca AZN1.05%increase; green up pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...